Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034
... the initiation of heparin therapy. It is primarily caused by the formation of antibodies against platelet factor 4 (PF4) and heparin. The diagnosis of Heparin-induced thrombocytopenia is based on a combination of clinical assessment, laboratory ... Read More
-
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
... the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenue generated during the study period (2020–2034). KRAZATI has been added as a therapeutic option after the first-line for treatment of NSCLC ... Read More
-
Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast - 2034
... to an increase in the cases and the launch of new therapies. The oligometastatic disease refers to a transitional state between localized and widespread disease. It typically involves one to five distant sites beyond the ... Read More
-
Postpartum Depression - Market Insights, Epidemiology, and Market Forecast - 2034
... of ~USD 25 Million in 2023. Among the seven major countries, the Postpartum Depression diagnosed prevalent cases were ~1,310,000, in 2023. In EU4 and the UK, the total Postpartum Depression diagnosed prevalent cases in Females ... Read More
-
B-cell Lymphoma- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage B-cell Lymphoma: Understanding B-cell Lymphoma: Overview ... Read More
-
Diabetic Nephropathy- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Diabetic Nephropathy: Understanding Diabetic Nephropathy: Overview ... Read More
-
Sarcopenia - Pipeline Insight, 2025
... covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Sarcopenia: Understanding Sarcopenia: Overview Sarcopenia is a ... Read More
-
Chronic Spinal Cord Injury- Pipeline Insight, 2025
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Chronic Spinal ... Read More
-
Huntington’s Disease - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Huntington’s Disease: Understanding Huntington’s Disease: ... Read More
-
Metastatic Colorectal Cancer - Pipeline Insight, 2025
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Metastatic Colorectal Cancer: ... Read More
-
Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Janus Kinase ... Read More
-
Microbiome Disease- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Microbiome Disease: Understanding Microbiome Disease: Overview ... Read More
-
Hypertriglyceridemia - Pipeline Insight, 2025
... covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Hypertriglyceridemia: Understanding Hypertriglyceridemia: Overview Hypertriglyceridemia is a ... Read More
-
5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2025
... detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered ... Read More
-
Angiotensin Receptor Agonist - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025
... of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the ... Read More
-
Sigma Receptor Agonist - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2025
... drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography ... Read More
-
TYK2 kinase inhibitors - Pipeline Insight, 2025
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage TYK2 Kinase Inhibitors ... Read More
-
ATPase Inhibitor - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2025
... Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental ... Read More
-
11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2025
... development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule ... Read More
-
5-HT2 Agonist - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage 5-HT2 Agonist: Understanding 5-HT2 Agonist: ... Read More
Research Assistance
